Acute myelogenous leukemia (AML) is a heterogeneous disease that is classified based on the morphology of the blasts and by the presence or absence of specific cytogenetic abnormalities. Two of the more common cytogenetic abnormalities, t(8;21) and inv(16), are seen in cases with different morphologies; however, recent studies have revealed that they have a common underlying pathogenesis and are therefore referred to collectively as the core binding factor leukemias (reviewed in Downing). These translocations result in the alteration of the genes that encode the AML1/CBF␤ core binding factor transcription complex, a critical regulator of normal hematopoiesis.
Acute myelogenous leukemia (AML) is a heterogeneous disease that is classified based on the morphology of the blasts and by the presence or absence of specific cytogenetic abnormalities. Two of the more common cytogenetic abnormalities, t(8;21) and inv(16), are seen in cases with different morphologies; however, recent studies have revealed that they have a common underlying pathogenesis and are therefore referred to collectively as the core binding factor leukemias (reviewed in Downing). These translocations result in the alteration of the genes that encode the AML1/CBF␤ core binding factor transcription complex, a critical regulator of normal hematopoiesis.
AML1 was initially identified as the target of the t(8;21) and was shown to encode a transcription factor that contained a central domain of approximately 100 amino acids that has a very high level of homology to the Drosophila pair-rules protein runt. AML1 binds to the core enhancer DNA sequence, TGT/GGT, through its central runt homology domain (RHD) and its affinity for DNA is increased by heterodimerization through the RHD with a second subunit called CBF␤. This heterodimeric transcription factor regulates the transcription of a large number of hematopoietic-specific targets, including but not limited to myeloperoxidase, CSF1 receptor, the subunits of the T cell antigen receptor, interleukin (IL)-3, and GM-CSF.
Although AML/CBF␤ was initially identified as the target of the t(8;21), subsequent work from a number of different laboratories has revealed that the genes encoding this transcription factor complex are some of the most frequent targets of chromosomal rearrangements in human acute leukemias. AML1 is altered by the t(12;21) in over 20% of pediatric acute lymphoblastic leukemias and by several rare translocations in AML. Similarly, CBF␤ has been demonstrated to be the target of the inv(16) seen in AML with M4-Eo morphology. Each of these translocations generates fusion proteins that retain the interactive domains of the respective core binding factor subunit and thus are predicted to interfere with the normal activity of AML1/CBF␤.
Gene targeting studies have shown that mice lacking AML1 are embryonic lethal due to the complete absence of fetal liver-derived hematopoiesis. 2 This functional defect has been shown to be intrinsic to the hematopoietic stem cells, suggesting that AML1/CBF␤ functions as a master regulatory switch that controls the formation of the definitive hematopoietic stem cell, or their survival, proliferation, and/or differentiation.
How do the leukemia-associated translocations perturb the normal function of AML1 and induce leukemia? The t(8;21) translocation results in the formation of a chimeric gene that encodes a fusion protein consisting of the amino-terminal portion of AML1 fused to the C-terminal portion of ETO. This Correspondence: J Downing Received 9 October 2000; accepted 30 October 2000 fusion protein retains the ability to bind to the core enhancer sequence and to interact with CBF-␤, however, instead of activating transcription, AML1-ETO functions as a transcriptional repressor, inhibiting the normal transcriptional activity of wild-type AML1/CBF␤. AML1/CBF␤ is predominantly a transcriptional activator in the early hematopoietic stem cell. It functions not as a simple heterodimeric transcription factor, but as an enhancer organizing protein that brings together different DNA binding proteins and transcriptional coactivators, ultimately associating with histone acetylases that allow transcriptional activation to occur. In contrast, AML-ETO, through the ETO moiety, brings together nuclear corepressors which deacetylase histone, leading to a repression of transcription.
These observations raise a dilemma, and that is, how can the loss of AML1 result in a complete absence of hematopoiesis, where as expression of a dominant negative inhibitor result not in the absence of hematopoiesis, but instead the complete opposite, leukemia? In order to address this paradox, we decided to directly assess the biologic function of the t(8;21)-encoded AML1-ETO fusion protein by generating a murine line that contains one normal AML1 allele and one allele in which ETO was knock-in to the AML1 genomic locus, thereby mimicking the t(8;21). If AML1-ETO functions as a dominant negative inhibitor of normal AML1/CBF␤, the prediction would be that expression of this allele would result in an embryonic lethal phenotype similar to that seen following the loss of AML or CBF␤. In fact this was the result observed. Expression of AML1-ETO resulted in an embryonic lethal phenotype almost identical to that seen following the loss of either AML1 or CBF␤, thus formally proving that AML1-ETO functions to interfere with the normal activity of AML1. 3 Importantly, however, although there was no morphologic evidence of hematopoietic progenitors in the AML1-ETO mice, hematopoietic progenitors were produced by the fetal livers ex vivo in methylcellulose cultures. These cells formed multilineage hematopoietic colonies that demonstrated dysplastic maturation. Moreover, in the wild-type mice, hematopoietic progenitor cells from the fetal liver stop forming colonies after several passages in methylcellulose, suggesting a limited self-renewal capacity. By contrast, the fetal progenitor cells from AML-ETO expressing mice could be passed indefinitely in cultures and readily formed immortalized cell lines in liquid cultures. Also of significance was that the AML1-ETO-expressing cells did not expand within the embryos and were unable to induce leukemia when transplanted into syngeneic recipients. Thus, these data suggest that AML1-ETO alters the self-renewal and maturation of hematopoietic stem cells resulting in the production of a preleukemic population. Expression of AML1-ETO by itself was not sufficient to induce a full leukemic phenotype. The nature of the secondary mutations that can co-operate with AML1-ETO remain to be defined. The diversity of mutations involved will likely provide critical insights into the clinical heterogeneity that exists among AML patient with this cytogenetic alteration. The varia-bility in those co-operating mutations undoubtedly influences which patients are going to respond to chemotherapy and which are not.
To formally address the range of secondary mutation that can co-operate with AML1-ETO, we have recently generated a murine line that contains a conditional AML1-ETO allele. 4 This allele allows us to bypass the embryonic lethality of AML1-ETO and to turn on the expression of the oncoprotein in adult mice. The approach used involved incorporating a strong transcriptional stop cassette bracketed by loxP recombination sites into the AML1 genomic locus. By using an inducible Cre transgene, this stop cassette can be deleted at will. Once deleted, AML1-ETO will be expressed under the control of the normal transcriptional regulatory sequences of AML1. Preliminary experiments have demonstrated that expression of AML1-ETO is insufficient to induce a full leukemic phenotype. Moreover, in proof-of-principle experiments, induction of secondary mutations with the DNA alkylating agent, ENU, resulted in the induction of leukemia.
Thus, this murine model should provide a powerful system to define the spectrum of secondary mutation that can co-operate with AML1-ETO to induce a full leukemic phenotype.
To summarize, AML1/CBF␤ is a master regulatory switch that controls the transcriptional cascade necessary for the formation of the definitive hematopoietic stem cell. AML-ETO functions primarily as a dominant negative inhibitor of the Leukemia normal transcriptional activity of AML1. By doing this, AML1-ETO induces the self-renewal of multipotential progenitors. Future experiments to define the range of secondary mutations able to co-operate with AML1-ETO will provide critical insights into the clinical variability seen in this patient subgroup and should help to identify targets against which novel therapeutic agents can be developed.
